Evaluation of a pharmacist-led actionable audit and feedback intervention for improving medication safety in UK primary care: An interrupted time series analysis
We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharm...
Uložené v:
| Vydané v: | PLoS medicine Ročník 17; číslo 10; s. e1003286 |
|---|---|
| Hlavní autori: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Public Library of Science
13.10.2020
Public Library of Science (PLoS) |
| Predmet: | |
| ISSN: | 1549-1676, 1549-1277, 1549-1676 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.
SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings.
The SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. |
|---|---|
| AbstractList | We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings. The SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings. The SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. Niels Peek and co-workers study a medication safety intervention in primary care in Salford, UK. To do this, we developed a novel electronic, interactive medication safety dashboard that identifies patients exposed to potential medication safety hazards and is updated on a daily basis [14], and capitalised on the National Health Service (NHS) England’s policy to increase clinical pharmacists working as part of general practice teams [15–17]. [...]pharmacists and practice staff were given access to a web-based, interactive dashboard that provided feedback on potentially hazardous prescribing. The dashboard also provided practice-level summary data (the number and percentage of patients who concurrently had risk factors for each indicator, comparisons with the average for each indicator across all practices, and patterns over time) as well as educational material (evidence summaries for each indicator, links to the relevant literature, and details of possible actions that could be taken for each indicator to reduce risk to patients). [...]pharmacists reviewed individual patients whose records triggered the indicators, and initiated remedial actions (e.g., ordering laboratory tests) or advised GPs on action plans (e.g., discontinuing medication, co-prescribing protective medication) [25,26]. Background We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. Methods and findings SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings. Conclusions The SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.BACKGROUNDWe evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.SMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings.METHODS AND FINDINGSSMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings.The SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices.CONCLUSIONSThe SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. To do this, we developed a novel electronic, interactive medication safety dashboard that identifies patients exposed to potential medication safety hazards and is updated on a daily basis [14], and capitalised on the National Health Service (NHS) England’s policy to increase clinical pharmacists working as part of general practice teams [15–17]. [...]pharmacists and practice staff were given access to a web-based, interactive dashboard that provided feedback on potentially hazardous prescribing. The dashboard also provided practice-level summary data (the number and percentage of patients who concurrently had risk factors for each indicator, comparisons with the average for each indicator across all practices, and patterns over time) as well as educational material (evidence summaries for each indicator, links to the relevant literature, and details of possible actions that could be taken for each indicator to reduce risk to patients). [...]pharmacists reviewed individual patients whose records triggered the indicators, and initiated remedial actions (e.g., ordering laboratory tests) or advised GPs on action plans (e.g., discontinuing medication, co-prescribing protective medication) [25,26]. BackgroundWe evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.Methods and findingsSMASH comprised (1) training of clinical pharmacists to deliver the intervention; (2) a web-based dashboard providing actionable, patient-level feedback; and (3) pharmacists reviewing individual at-risk patients, and initiating remedial actions or advising general practitioners on doing so. It was implemented in 43 general practices covering a population of 235,595 people in Salford (Greater Manchester), UK. All practices started receiving the intervention between 18 April 2016 and 26 September 2017. We used an interrupted time series analysis of rates (prevalence) of potentially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-intervention to extrapolations from a 24-month pre-intervention trend. The number of people registered to participating practices and having 1 or more risk factors for being exposed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention was 47,413 (males: 23,073 [48.7%]; mean age: 60 years [standard deviation: 21]). At baseline, 95% of practices had rates of potentially hazardous prescribing (composite of 10 indicators) between 0.88% and 6.19%. The prevalence of potentially hazardous prescribing reduced by 27.9% (95% CI 20.3% to 36.8%, p < 0.001) at 24 weeks and by 40.7% (95% CI 29.1% to 54.2%, p < 0.001) at 12 months after introduction of SMASH. The rate of inadequate blood-test monitoring (composite of 2 indicators) reduced by 22.0% (95% CI 0.2% to 50.7%, p = 0.046) at 24 weeks; the change at 12 months (23.5%) was no longer significant (95% CI -4.5% to 61.6%, p = 0.127). After 12 months, 95% of practices had rates of potentially hazardous prescribing between 0.74% and 3.02%. Study limitations include the fact that practices were not randomised, and therefore unmeasured confounding may have influenced our findings.ConclusionsThe SMASH intervention was associated with reduced rates of potentially hazardous prescribing and inadequate blood-test monitoring in general practices. This reduction was sustained over 12 months after the start of the intervention for prescribing but not for monitoring of medication. There was a marked reduction in the variation in rates of hazardous prescribing between practices. |
| Audience | Academic |
| Author | Williams, Richard Kontopantelis, Evangelos Keers, Richard N. Phipps, Denham L. Ashcroft, Darren M. Peek, Niels Avery, Anthony J. Jeffries, Mark Brown, Benjamin Gude, Wouter T. |
| AuthorAffiliation | 3 Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom 2 NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom 6 Pharmacy Department, Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom 4 Department of Medical Informatics, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, Netherlands 9 Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom NHS Greater Glasgow and Clyde, UNITED KINGDOM 7 NIHR School for Primary Care Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom 8 Centre for Primary Care, Division of Population Health, Health Services Research a |
| AuthorAffiliation_xml | – name: 4 Department of Medical Informatics, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, Netherlands – name: 2 NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom – name: 1 NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom – name: 7 NIHR School for Primary Care Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom – name: 3 Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom – name: 8 Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom – name: 5 Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom – name: 6 Pharmacy Department, Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom – name: 9 Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom – name: NHS Greater Glasgow and Clyde, UNITED KINGDOM |
| Author_xml | – sequence: 1 givenname: Niels orcidid: 0000-0002-6393-9969 surname: Peek fullname: Peek, Niels – sequence: 2 givenname: Wouter T. orcidid: 0000-0001-7941-5281 surname: Gude fullname: Gude, Wouter T. – sequence: 3 givenname: Richard N. orcidid: 0000-0001-7854-8154 surname: Keers fullname: Keers, Richard N. – sequence: 4 givenname: Richard orcidid: 0000-0002-0920-1103 surname: Williams fullname: Williams, Richard – sequence: 5 givenname: Evangelos orcidid: 0000-0001-6450-5815 surname: Kontopantelis fullname: Kontopantelis, Evangelos – sequence: 6 givenname: Mark orcidid: 0000-0002-6882-0350 surname: Jeffries fullname: Jeffries, Mark – sequence: 7 givenname: Denham L. orcidid: 0000-0003-0857-2890 surname: Phipps fullname: Phipps, Denham L. – sequence: 8 givenname: Benjamin orcidid: 0000-0001-9975-4782 surname: Brown fullname: Brown, Benjamin – sequence: 9 givenname: Anthony J. orcidid: 0000-0001-7591-4438 surname: Avery fullname: Avery, Anthony J. – sequence: 10 givenname: Darren M. orcidid: 0000-0002-2958-915X surname: Ashcroft fullname: Ashcroft, Darren M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33048923$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVk91qFDEUxwep2A99A9FAQfRi12SSycz0QiilarFYUOttOJNJdlMzkzXJLPZxfFMz3W3plkWUuciQ8zv_85Wzn-30rldZ9pzgKaEleXvlBt-DnS461U4JxjSv-KNsjxSsnhBe8p17_7vZfghXGOc1rvGTbJdSzKo6p3vZ79Ml2AGicT1yGgFazMF3IE2IE6taBHI0QWMVgqE1EUHfIq1U24D8gUwflV-q_sZdO49Mt_BuafoZSlkZudINoFW8TjC6_IQW3nTgr5EEr47Qcb_S8MMipmjRdAoF5Y0KKRDY62DC0-yxBhvUs_V5kF2-P_128nFyfvHh7OT4fCJLzuKk4FXBNWnygrOmrTltKqCM8ZxD2ZAaF8BKraVkMpkZbaEgUBPalBqaqtKMHmQvV7oL64JYdzeInJU14xXnPBFnK6J1cCXWhQgHRtxcOD8T4KORVolG1qSkTEvc1IzgtmIVJlLjWqkCcEOS1rt1tKFJrZKphx7shuimpTdzMXNLURYFpXRM5vVawLufgwpRdCZIZS30yg1j3gUhlBGeJ_TwAbq9ujU1g1SA6bVLceUoKo45y_PUzLJO1GQLNVO9SkmmB6pNut7gp1v49LWqM3Krw5sNh8RE9SvOYAhBnH398h_s539nL75vsq_usXMFNs6Ds8P4msMm-OL-FO_Gd7tfCWArQHoXglf6DiFYjGt8OwoxrrFYr3FyO3rgJk28WabUPWP_7vwHK59O5w |
| CitedBy_id | crossref_primary_10_1371_journal_pmed_1004133 crossref_primary_10_1093_fampra_cmaf036 crossref_primary_10_1007_s40278_020_84766_2 crossref_primary_10_1186_s12888_022_04235_0 crossref_primary_10_1093_jamia_ocac031 crossref_primary_10_1136_dtb_2024_000066 crossref_primary_10_12688_hrbopenres_13909_2 crossref_primary_10_1136_bmjqs_2025_018794 crossref_primary_10_1186_s12916_024_03489_7 crossref_primary_10_12688_hrbopenres_13909_1 crossref_primary_10_1111_bcp_15107 crossref_primary_10_1136_bmjopen_2023_083620 crossref_primary_10_1371_journal_pone_0253588 crossref_primary_10_1186_s12874_024_02184_8 crossref_primary_10_1136_bmjopen_2023_081934 crossref_primary_10_1016_j_pcd_2021_06_003 crossref_primary_10_1136_bmjopen_2024_086309 crossref_primary_10_1016_j_ijmedinf_2025_106089 crossref_primary_10_1007_s11096_022_01420_9 crossref_primary_10_1186_s13012_022_01203_w crossref_primary_10_1111_1475_6773_14363 crossref_primary_10_1136_bmjqs_2021_013427 |
| Cites_doi | 10.2105/AJPH.94.3.361 10.1186/s12911-020-1084-5 10.1136/bmj.h5501 10.1016/0021-9681(87)90171-8 10.1056/NEJMsa020847 10.15265/IY-2017-004 10.1023/A:1024068817085 10.1136/amiajnl-2012-001484 10.1111/bcp.13006 10.1186/s12913-017-2131-5 10.3399/bjgp18X698849 10.1371/journal.pone.0069930 10.1136/bmj.l4185 10.1345/aph.1P627 10.1177/1536867X1501500208 10.1136/bmj.i5834 10.1136/bmj.g1687 10.1177/1536867X1001000307 10.1016/S0140-6736(17)31047-4 10.1002/sim.1186 10.1016/j.sapharm.2017.04.014 10.1136/bmj.h2750 10.3399/bjgp17X690437 10.1111/ijpp.12032 10.1016/j.sapharm.2018.06.001 10.1136/amiajnl-2013-001813 10.1371/journal.pone.0205419 10.1136/bmj.i1114 10.1007/s40264-015-0304-x 10.1111/ijpp.12426 10.1186/s12916-017-0781-0 10.1056/NEJMsa1508955 10.1186/s13012-017-0590-z 10.1016/S0140-6736(11)61817-5 10.1002/sim.7431 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 Public Library of Science 2020 Peek et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 Peek et al 2020 Peek et al |
| Copyright_xml | – notice: COPYRIGHT 2020 Public Library of Science – notice: 2020 Peek et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 Peek et al 2020 Peek et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISN ISR 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA CZK |
| DOI | 10.1371/journal.pmed.1003286 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science ProQuest Central (Corporate) Neurosciences Abstracts Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text PLoS Medicine |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Evaluation of a pharmacist-led actionable audit and feedback intervention to improve medication safety |
| EISSN | 1549-1676 |
| ExternalDocumentID | 2479468666 oai_doaj_org_article_bc91734fc0b9410d84801cf09ee5a0b1 PMC7553336 A642234479 33048923 10_1371_journal_pmed_1003286 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom United Kingdom--UK England United States--US |
| GeographicLocations_xml | – name: United Kingdom – name: England – name: United Kingdom--UK – name: United States--US |
| GrantInformation_xml | – fundername: Department of Health – fundername: Medical Research Council grantid: MR/K006665/1 – fundername: ; grantid: MR/K006665/1 – fundername: ; grantid: PSTRC-2016-003 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAUCC AAWOE AAWTL AAYXX ABDBF ABUWG ACCTH ACGFO ACIHN ACPRK ACUHS ADBBV AEAQA AENEX AFFHD AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAIFH BAWUL BBTPI BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IOF IOV IPO ISN ISR ITC KQ8 M1P M48 MK0 O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PV9 RNS RPM RZL SV3 TR2 TUS UKHRP WOW XSB YZZ ~8M ADRAZ ADXHL ALIPV CGR CUY CVF ECM EIF H13 IPNFZ NPM RIG WOQ 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM - AAPBV ABPTK ADACO BBAFP BCGST CZK ICW M~E |
| ID | FETCH-LOGICAL-c764t-56856f1b2564bd963b8a344626a7b1905a47ffcc4c4bd43da51a913b7fab88f43 |
| IEDL.DBID | FPL |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000581721000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1549-1676 1549-1277 |
| IngestDate | Fri Nov 26 17:12:39 EST 2021 Fri Oct 03 12:51:27 EDT 2025 Tue Nov 04 01:58:09 EST 2025 Wed Oct 01 12:53:35 EDT 2025 Sat Nov 29 14:37:33 EST 2025 Tue Nov 11 10:44:20 EST 2025 Sat Nov 29 11:48:29 EST 2025 Tue Nov 04 17:50:11 EST 2025 Thu Nov 13 14:25:44 EST 2025 Thu Nov 13 14:37:31 EST 2025 Thu Nov 13 15:42:07 EST 2025 Thu May 22 20:53:57 EDT 2025 Mon Jul 21 06:04:57 EDT 2025 Sat Nov 29 05:34:06 EST 2025 Tue Nov 18 22:26:59 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c764t-56856f1b2564bd963b8a344626a7b1905a47ffcc4c4bd43da51a913b7fab88f43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 I have read the journal's policy and the authors of this manuscript have the following competing interests: RNK has received an honorarium for presenting on the topic of schizophrenia (epidemiology, aetiology, presentation and management) at the MORPh Consultancy Ltd Primary Care Pharmacists Training Network Mental Health Event, on 23rd October 2019, Liverpool UK. |
| ORCID | 0000-0002-6393-9969 0000-0001-7941-5281 0000-0002-0920-1103 0000-0001-6450-5815 0000-0003-0857-2890 0000-0002-2958-915X 0000-0001-9975-4782 0000-0001-7854-8154 0000-0001-7591-4438 0000-0002-6882-0350 |
| OpenAccessLink | http://dx.doi.org/10.1371/journal.pmed.1003286 |
| PMID | 33048923 |
| PQID | 2479468666 |
| PQPubID | 1436338 |
| ParticipantIDs | plos_journals_2479468666 doaj_primary_oai_doaj_org_article_bc91734fc0b9410d84801cf09ee5a0b1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7553336 proquest_miscellaneous_2451134162 proquest_journals_2479468666 gale_infotracmisc_A642234479 gale_infotracgeneralonefile_A642234479 gale_infotracacademiconefile_A642234479 gale_incontextgauss_ISR_A642234479 gale_incontextgauss_ISN_A642234479 gale_incontextgauss_IOV_A642234479 gale_healthsolutions_A642234479 pubmed_primary_33048923 crossref_primary_10_1371_journal_pmed_1003286 crossref_citationtrail_10_1371_journal_pmed_1003286 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-13 |
| PublicationDateYYYYMMDD | 2020-10-13 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PLoS medicine |
| PublicationTitleAlternate | PLoS Med |
| PublicationYear | 2020 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | M Panagioti (pmed.1003286.ref002) 2019; 366 DW Bates (pmed.1003286.ref007) 2003; 348 AJ Avery (pmed.1003286.ref012) 2012; 379 pmed.1003286.ref040 ACM Hazen (pmed.1003286.ref044) 2018; 14 M Aitken (pmed.1003286.ref003) 2012 M Jeffries (pmed.1003286.ref026) 2017; 17 DR Morales (pmed.1003286.ref037) 2016; 82 DR Morales (pmed.1003286.ref038) 2017; 15 A Akbarov (pmed.1003286.ref021) 2015; 38 G Iacobucci (pmed.1003286.ref047) 2016; 355 TC Hoffmann (pmed.1003286.ref019) 2014; 348 KC Nanji (pmed.1003286.ref009) 2014; 21 M Petropoulou (pmed.1003286.ref032) 2017; 36 J Bush (pmed.1003286.ref043) 2018; 26 T Tuti (pmed.1003286.ref010) 2017; 12 pmed.1003286.ref028 pmed.1003286.ref005 R Williams (pmed.1003286.ref014) 2018; 25 pmed.1003286.ref027 E Kontopantelis (pmed.1003286.ref034) 2010; 10 TREND Group (pmed.1003286.ref018) 2004; 94 PTW Hudson (pmed.1003286.ref011) 2003; 25 SJ Stocks (pmed.1003286.ref006) 2015; 351 JP New (pmed.1003286.ref022) 2018; 360 J Hayward (pmed.1003286.ref008) 2013; 20 S Rodgers (pmed.1003286.ref020) 2018 T Dreischulte (pmed.1003286.ref041) 2016; 374 M Jeffries (pmed.1003286.ref025) 2018; 13 C Anderson (pmed.1003286.ref015) 2019; 15 SV Taché (pmed.1003286.ref004) 2011; 45 N Ivers (pmed.1003286.ref013) 2012; 6 S Sadler (pmed.1003286.ref024) 2014; 22 LJ Donaldson (pmed.1003286.ref001) 2017; 389 E Kontopantelis (pmed.1003286.ref031) 2015; 350 E Kontopantelis (pmed.1003286.ref033) 2013; 8 R Keers (pmed.1003286.ref036) 2018; 27 CP Friedman (pmed.1003286.ref045) 2017; 26 ME Charlson (pmed.1003286.ref046) 1987; 40 F Bradley (pmed.1003286.ref016) 2018; 68 S MacBride-Stewart (pmed.1003286.ref042) 2017; 67 M Jeffries (pmed.1003286.ref039) 2020; 20 S Stevens (pmed.1003286.ref030) 2016; 352 pmed.1003286.ref017 A Linden (pmed.1003286.ref029) 2015; 15 JPT Higgins (pmed.1003286.ref035) 2002; 21 National Institute for Health and Care Excellence (pmed.1003286.ref023) 2018 |
| References_xml | – volume-title: Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes year: 2018 ident: pmed.1003286.ref023 – volume: 94 start-page: 361 issue: 3 year: 2004 ident: pmed.1003286.ref018 article-title: Standards for reporting non-randomized evaluations of behavioral and public health interventions: the TREND statement publication-title: Am J Public Health doi: 10.2105/AJPH.94.3.361 – volume: 20 start-page: 69 issue: 1 year: 2020 ident: pmed.1003286.ref039 article-title: Understanding the utilisation of a novel interactive electronic medication safety dashboard in general practice: a mixed methods study publication-title: BMC Med Inform Decis Mak doi: 10.1186/s12911-020-1084-5 – volume: 351 start-page: h5501 year: 2015 ident: pmed.1003286.ref006 article-title: Examining variations in prescribing safety in UK general practice: cross sectional study using the Clinical Practice Research Datalink publication-title: BMJ doi: 10.1136/bmj.h5501 – volume: 40 start-page: 373 year: 1987 ident: pmed.1003286.ref046 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – volume: 348 start-page: 2526 year: 2003 ident: pmed.1003286.ref007 article-title: Improving safety with information technology publication-title: N Engl J Med doi: 10.1056/NEJMsa020847 – volume: 26 start-page: 16 year: 2017 ident: pmed.1003286.ref045 article-title: Toward an information infrastructure for global health improvement publication-title: Yearb Med Inform doi: 10.15265/IY-2017-004 – volume: 25 start-page: 98 year: 2003 ident: pmed.1003286.ref011 article-title: Risk assessment in clinical pharmacy publication-title: Pharm World Sci doi: 10.1023/A:1024068817085 – ident: pmed.1003286.ref028 – ident: pmed.1003286.ref005 – year: 2012 ident: pmed.1003286.ref003 article-title: Advancing the responsible use of medicines: applying levers for change publication-title: SSRN – volume: 20 start-page: e76 year: 2013 ident: pmed.1003286.ref008 article-title: ‘Too much, too late’: mixed methods multi-channel video recording study of computerized decision support systems and GP prescribing publication-title: J Am Med Inform Assoc doi: 10.1136/amiajnl-2012-001484 – volume: 82 start-page: 814 year: 2016 ident: pmed.1003286.ref037 article-title: Respiratory effect of beta‐blocker eye drops in asthma: population‐based study and meta‐analysis of clinical trials publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13006 – volume: 17 start-page: 196 year: 2017 ident: pmed.1003286.ref026 article-title: Understanding the implementation and adoption of a technological intervention to improve medication safety in primary care: a realist evaluation publication-title: BMC Health Serv Res doi: 10.1186/s12913-017-2131-5 – volume: 68 start-page: e727 year: 2018 ident: pmed.1003286.ref016 article-title: Evolution of the general practice pharmacist’s role in England: a longitudinal study publication-title: Br J Gen Pract doi: 10.3399/bjgp18X698849 – volume: 25 start-page: 183 year: 2018 ident: pmed.1003286.ref014 article-title: SMASH! The Salford medication safety dashboard publication-title: J Innov Health Inform – volume: 8 start-page: e69930 year: 2013 ident: pmed.1003286.ref033 article-title: A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses publication-title: PLoS ONE doi: 10.1371/journal.pone.0069930 – volume: 366 start-page: l4185 year: 2019 ident: pmed.1003286.ref002 article-title: Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis publication-title: BMJ doi: 10.1136/bmj.l4185 – volume: 45 start-page: 977 year: 2011 ident: pmed.1003286.ref004 article-title: Prevalence of adverse drug events in ambulatory care: a systematic review publication-title: Ann Pharmacother doi: 10.1345/aph.1P627 – volume: 15 start-page: 480 year: 2015 ident: pmed.1003286.ref029 article-title: Conducting interrupted time-series analysis for single- and multiple-group comparisons publication-title: Stata J doi: 10.1177/1536867X1501500208 – volume: 355 start-page: i5834 year: 2016 ident: pmed.1003286.ref047 article-title: General practices achieve 95% of QOF points publication-title: BMJ doi: 10.1136/bmj.i5834 – ident: pmed.1003286.ref017 – ident: pmed.1003286.ref040 – volume: 348 start-page: g1687 year: 2014 ident: pmed.1003286.ref019 article-title: Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide publication-title: BMJ doi: 10.1136/bmj.g1687 – volume: 10 start-page: 395 year: 2010 ident: pmed.1003286.ref034 article-title: Metaan: Random-effects meta-analysis publication-title: Stata J doi: 10.1177/1536867X1001000307 – volume: 389 start-page: 1680 year: 2017 ident: pmed.1003286.ref001 article-title: Medication without harm: WHO’s Third Global Patient Safety Challenge publication-title: Lancet doi: 10.1016/S0140-6736(17)31047-4 – volume: 6 start-page: CD000259 year: 2012 ident: pmed.1003286.ref013 article-title: Audit and feedback: effects on professional practice and healthcare outcomes publication-title: Cochrane Database Syst Rev – volume: 21 start-page: 1539 year: 2002 ident: pmed.1003286.ref035 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 14 start-page: 228 year: 2018 ident: pmed.1003286.ref044 article-title: The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: a systematic review publication-title: Res Social Adm Pharm doi: 10.1016/j.sapharm.2017.04.014 – volume: 350 start-page: h2750 year: 2015 ident: pmed.1003286.ref031 article-title: Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis publication-title: BMJ doi: 10.1136/bmj.h2750 – volume: 67 start-page: e352 year: 2017 ident: pmed.1003286.ref042 article-title: Evaluation of a complex intervention to improve primary care prescribing: a phase IV segmented regression interrupted time series analysis publication-title: Br J Gen Pract doi: 10.3399/bjgp17X690437 – volume: 360 start-page: j5554 year: 2018 ident: pmed.1003286.ref022 article-title: Putting patients in control of data from electronic health records publication-title: BMJ – volume: 22 start-page: 47 year: 2014 ident: pmed.1003286.ref024 article-title: Training pharmacists to deliver a complex information technology intervention (PINCER) using the principles of educational outreach and root cause analysis publication-title: Int J Pharm Pract doi: 10.1111/ijpp.12032 – volume: 15 start-page: 338 year: 2019 ident: pmed.1003286.ref015 article-title: The role of pharmacists in general practice: a realist review publication-title: Res Social Adm Pharm doi: 10.1016/j.sapharm.2018.06.001 – ident: pmed.1003286.ref027 – volume: 27 start-page: O15 year: 2018 ident: pmed.1003286.ref036 article-title: Improving medication safety in primary care: developing a stakeholder-centred electronic prescribing safety indicator dashboard publication-title: Pharmacoepidemiol Drug Saf – volume: 21 start-page: 487 year: 2014 ident: pmed.1003286.ref009 article-title: Overrides of medication-related clinical decision support alerts in outpatients publication-title: J Am Med Inform Assoc doi: 10.1136/amiajnl-2013-001813 – volume: 13 start-page: e0205419 year: 2018 ident: pmed.1003286.ref025 article-title: Developing a learning health system: insights from a qualitative process evaluation of a pharmacist-led electronic audit and feedback intervention to improve medication safety in primary care publication-title: PLoS ONE doi: 10.1371/journal.pone.0205419 – volume: 352 start-page: i1114 year: 2016 ident: pmed.1003286.ref030 article-title: Analysing indicators of performance, satisfaction, or safety using empirical logit transformation publication-title: BMJ doi: 10.1136/bmj.i1114 – volume: 38 start-page: 671 year: 2015 ident: pmed.1003286.ref021 article-title: Primary care medication safety surveillance with integrated primary and secondary care electronic health records: a cross-sectional study publication-title: Drug Saf doi: 10.1007/s40264-015-0304-x – volume: 26 start-page: 501 year: 2018 ident: pmed.1003286.ref043 article-title: Clinical pharmacists in general practice: an initial evaluation of activity in one English primary care organisation publication-title: Int J Pharm Pract doi: 10.1111/ijpp.12426 – volume-title: Improving medication safety in general practices in the East Midlands through the PINCER intervention: scaling up PINCER year: 2018 ident: pmed.1003286.ref020 – volume: 15 start-page: 18 year: 2017 ident: pmed.1003286.ref038 article-title: Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study publication-title: BMC Med doi: 10.1186/s12916-017-0781-0 – volume: 374 start-page: 1053 year: 2016 ident: pmed.1003286.ref041 article-title: Safer prescribing—a trial of education, informatics, and financial incentives publication-title: N Engl J Med doi: 10.1056/NEJMsa1508955 – volume: 12 start-page: 61 year: 2017 ident: pmed.1003286.ref010 article-title: A systematic review of electronic audit and feedback: Intervention effectiveness and use of behaviour change theory publication-title: Implement Sci doi: 10.1186/s13012-017-0590-z – volume: 379 start-page: 1310 year: 2012 ident: pmed.1003286.ref012 article-title: A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis publication-title: Lancet doi: 10.1016/S0140-6736(11)61817-5 – volume: 36 start-page: 4266 year: 2017 ident: pmed.1003286.ref032 article-title: A comparison of 20 heterogeneity variance estimators in statistical synthesis of results from studies: a simulation study publication-title: Stat Med doi: 10.1002/sim.7431 |
| SSID | ssj0029090 |
| Score | 2.4455822 |
| Snippet | We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.
SMASH comprised (1)... Background We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. Methods and... We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care. SMASH comprised (1)... To do this, we developed a novel electronic, interactive medication safety dashboard that identifies patients exposed to potential medication safety hazards... We evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.BACKGROUNDWe evaluated the... Niels Peek and co-workers study a medication safety intervention in primary care in Salford, UK. BackgroundWe evaluated the impact of the pharmacist-led Safety Medication dASHboard (SMASH) intervention on medication safety in primary care.Methods and... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e1003286 |
| SubjectTerms | Adult Ambulatory care Audits Community Pharmacy Services - trends Computerized physician order entry Data warehouses Drug Prescriptions Electronic Health Records Feedback Female General Practice - methods Humans Interrupted Time Series Analysis - methods Intervention Laboratories Male Medical errors Medication errors Medication Errors - prevention & control Medicine and Health Sciences Methods Middle Aged Patient safety People and Places Pharmaceutical care Pharmacists Physical Sciences Prevention Primary care Primary health care Primary Health Care - methods Quality management Risk Factors Safety Safety - statistics & numerical data Time series United Kingdom |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA6yiPgi_r7qqVFEn-q1Tdqkvq1yhyKuop7cW0nS5FxcumW7K_jn-J8602TLVhbuHnxtvqY0M0lmkplvCHluM16r3LhYC6Vi7qyOJZgZMZOcM6sLZxNfbELMZvLsrPy8U-oLY8I8PbAfuCNtwKFg3JlElzxNaol8J8YlpbW5SnTv-CSi3DpTwdUqk_50BfnH4jQTIiTNMZEeBRm9amG3wRgB1udR72xKPXf_sEJP2sWy22d-_htFubMtndwkN4I9Saf-P26RK7a5Ta59DDfmd8if44HOmy4dVbT1XNUg3Xhha-rzGjB_iipM0KCqqamDLU0r85POdyIiKZi3dL49g6D9pbzvt1POrn8DmJ5-oK2nr6AYUvaaThvfx2rTgmlLsZI9RaW3HXzI06HcJacnx9_evotDWYbYiIKv47yQeeFSDcYS1zVMYC0VA68yK5TQYF_kigvnjOEGmjkDVUhVmTItnNJSOs7ukUmzbOwBoa4EEdYuTZwpuAXRyrx2liuNn2BcRoRt5VKZwFmOpTMWVX8RJ8B38cNcoTSrIM2IxMNb4acvwL9BkQ9YZNzuH4AeVkEPq4v0MCJPUGEqn746rBvVFBy8DGkVy4g86xHIutFgWM-52nRd9f7T90uAvs4uA_oyAr0MILeEMTMq5FvAyCPl1wj5YoQ894Tn-4CHIyCsRGbUfICTZTvGXZX15QskeMjw5nYC7W9-OjRjpxj419jlBjHgEYClVWQRue_n2yAnPIqT4KBERIxm4kiQ45Zm_qOnUBc5uDmsePA_JP-QXM_wEAbDnNghmaxXG_uIXDW_1vNu9bhfl_4CdRaUkw priority: 102 providerName: Directory of Open Access Journals – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELagixAX3rCBBQxCcApNYufFBRW0K1ZoywpYtJwi27FLRUlK0yLxc_inzMRuaFAFe-Baf0lqe2Y8Y898JuSxjngpYmV8mQrhc6Oln4Gb4bOMc6ZlYnRgL5tIx-Ps9DQ_duXRjUurXNvE1lBbtmfM2wYjPCxrhTvmw6glRs_A934x_-bjHVJ41uou1DhPdpB4KxiQnePDo-NPXQCWB-2eC7KS-WGUpq6UjqXh0M3cszmsQZg5wNrq6o2lqmX07-z2YD6rm21O6Z-5lRuL1cGV_9vNq-Syc1rpyErZNXJOV9fJxSN3LH-D_NzvOMNpbaigc0uIDSLkz3RJbfEEFmlRgVUgVFQlNbBuSqG-0OlG2iUFH5pO1xsdtD35t-9thNHLHwCmJ2_o3HJkUMxbe05HlX3HYjUH_5kup181Rc3SDXzIcq7cJCcH-x9evfbd3Q--ShO-9OMkixMTSvDIuCzBSshMMAhdo0SkEpyYWPDUGKW4gmbOQN5CkYdMpkbILDOc3SKDqq70LqEmF4EsTRgYlXCdgcWKS6O5kPgJxjOPsPU0F8oRo-P9HLOiPe1LIUCyw1ygcBROODzid0-5Tv8D_xIlqMMirXf7Q72YFM5KFFJB9My4UYHMeRiUGZL7KBPkWsfQidAjD1D-Clsj2xmnYgRRZITcjblHHrUIpPaoMHdoIlZNUxy-_XgG0PvxWUDveqCnDmRqGDMlXFEHjDzyivWQT3rIiWVV3wbc6wHB3Kle8y7q3nqMm-K3jsCTa53a3vywa8aXYnZhpesVYiDsAHcuiTxy26pvN0-435dBFOSRtKfYvYnst1TTzy1PexpDLMWSO3__W3fJpQj3cDBLiu2RwXKx0vfIBfV9OW0W950J-wV26a_D priority: 102 providerName: ProQuest |
| Title | Evaluation of a pharmacist-led actionable audit and feedback intervention for improving medication safety in UK primary care: An interrupted time series analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33048923 https://www.proquest.com/docview/2479468666 https://www.proquest.com/docview/2451134162 https://pubmed.ncbi.nlm.nih.gov/PMC7553336 https://doaj.org/article/bc91734fc0b9410d84801cf09ee5a0b1 http://dx.doi.org/10.1371/journal.pmed.1003286 |
| Volume | 17 |
| WOSCitedRecordID | wos000581721000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: BENPR dateStart: 20041001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Health and Medical Complete customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: 7X7 dateStart: 20041001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: PIMPY dateStart: 20041001 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: FPL dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdYhxAvfMMKoxiE4CmQxE7s8NahVkywUg2GuqfIduxRUaVV0yLx5_CfcpekYZk6MV7yEP-cj7PPvrN9vyPkpQ15piLjPC2U8riz2pNgZnhMcs6sjp31q2QTYjSSk0ky_usoXtjBZyJ4W8v0zQJmB9zTZ6GMd8huyOIYUzUMx58aByvxE78Oj7usZmv6KVn6m7G4s5jNi22G5sXzkucmoOHt__30O-RWbWrSftU37pJrNr9HbhzVm-n3ye9Bw_RN544quqhorKHhvZnNaBXygKFVVGHsBlV5Rh3MdlqZH3R67rAkBcuXTjfLE7Tcr6-eWyhnV78ATE8-0kXFbEHxtNk72s-rZyzXC7B6KSa5p6gPtoAXVUwpD8jJcPD1_QevztjgGRHzlRfFMopdoMGO4joD3dZSMXA4w1gJDaZHpLhwzhhuoJgz6CWBSgKmhVNaSsfZQ9LJ57ndI9QlyteZC3xnYm4ljDNR5ixXGl_BuOwStmnI1NR05phVY5aWe3QC3JpKzClKP62l3yVeU6v-6X_gD7CPNFgk4y5vQDOntW6n2oDPy7gzvk544GcSKXmM8xNrI_iJoEueYQ9Lq8jWZkhJ--D7hci4mHTJixKBhBw5nvg5U-uiSA8_f7sC6MvoKqDjFuh1DXJzkJlRdSgGSB7ZwFrIVy3kWcWFvg243wLCIGVaxXuoXRsZF2lYZjaQ4DxDzY3GbS9-3hTjQ_FMYG7na8SAswBGWBx2yaNKQZt2wlU6Cb5Ll4iW6rYasl2ST7-X7OoiAg-IxY8v_-In5GaIqy54rontk85qubZPyXXzczUtlj2yIyaivMoe2T0YjMbHvXKlp1cOVnBvfHg0Pv0DioqVEA |
| linkProvider | Public Library of Science |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbKFgEX3tCFQg3icQpNYidOkBAq0KqrtktVWlROwXbssqIky2YX1J_DH-A3MpMXDaqglx64rr846_F4xuPMfCbkkfF5KgNtHSWkdLg1yolgm-GwiHNmVGiNW102IYbDaH8_3p4jP5taGEyrbGxiaajTXOMZ-bJfUqFHsNt-Of7q4K1R-HW1uUKjUosNc_QdQrbixeANzO9j319b3X297tS3CjhahHzqBGEUhNZT4Ou5SkH_VCQZBEV-KIUC9xhILqzVmmto5gxG4snYY0pYqaLIcgb9niPzHJTd7ZH57cHW9oc2xIvd8lQHec8czxeiLtZjwluudePZGLwc5iawsn77mDMs7wxoPUNvfJgXJ217_8zePOYO1678b4K8Si7XG2-6Uq2Ua2TOZNfJha06teAG-bHa8p7T3FJJxxWpNywD59CktCoAwUIzKrGShcospRZ8v5L6Mx0dSx2lEAfQUXNYQ8vsharfQlozPQIw3dug44rng2Lu3XO6klV9TGZjiAHodPTFULQOpoAXVbwxN8nemQjoFulleWYWCLWxdFVqPdfqkJsIrG6QWsOlwlcwHvUJaxQp0TW5O94xcpiUXywFBHmVmBNUv6RWvz5x2qfqQf8D_wp1tMUiNXn5Qz45SGpLlygde4Jxq10Vc89NIyQo0taNjQlgEF6fLKGGJ1Wdb2tgkxWIhH3kn4z75GGJQHqSDPOfDuSsKJLB2_enAL0bnga00wE9rUE2B5lpWRemgOSRG62DfNJBHlTM8CcBFztAMNm607yAq7uRcZH8XpPwZLNqT25-0DZjp5ghmZl8hhgInWBLGvp9crsyEO084ZllBJFcn4iO6ehMZLclG30queZFAPEgC-_8_W8tkYvru1ubyeZguHGXXPLxTAqzvtgi6U0nM3OPnNffpqNicr82mJR8PGvT8gvD3AEV |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbKFlVceEMXCjWIxyk0iZ0XEkJb2oqqsFQtRb0F27HLiiVZNrug_hz-Br-OmcQJDaqglx64rr84a3seHmfmMyGPtM8zESjjyEgIhxstnRi2GQ6LOWdahka79WUT0XAYHx4muwvkZ1MLg2mVjU2sDHVWKDwjX_MrKvQYdttrxqZF7G5svZx8dfAGKfzS2lynUYvIjj7-DuFb-WJ7A9b6se9vbb5_9dqxNww4Kgr5zAnCOAiNJ8Hvc5mBLMpYMAiQ_FBEElxlIHhkjFJcQTNnMCpPJB6TkREyjg1n0O8FshgxCHp6ZHF9c7i714Z7iVud8CAHmuP5UWQL91jkrVk5eTYBj4d5Cqyq5T7hGKv7A1ov0ZuMi_K0LfCfmZwnXOPWlf95Uq-Sy3ZDTge1Bl0jCzq_Tpbe2pSDG-THZsuHTgtDBZ3UZN-gHs5YZ7QuDMECNCqwwoWKPKMG9gRSqM90dCKllEJ8QEfNIQ6tshrqfkth9OwYwPRgh05q_g-KOXnP6SCv-5jOJxAb0Nnoi6ZoNXQJL6r5ZG6Sg3OZoFuklxe5XibUJMKVmfFco0KuY7DGQWY0FxJfwXjcJ6wRqlRZ0ne8e2ScVl8yIwj-6mlOURRTK4p94rRP2UH_A7-O8tpikbK8-qGYHqXWAqZSgZIwbpQrE-65WYzERcq4idYBDMLrk1WU9rSu_20NbzqACNlHXsqkTx5WCKQtyVFWj8S8LNPtdx_OANofngW01wE9tSBTwJwpYQtWYOaRM62DfNJBHtWM8acBVzpAMOWq07yMmt7McZn-1k94stHg05sftM3YKWZO5rqYIwZCKtiqhn6f3K6NRbtOeJYZQ4TXJ1HHjHQWstuSjz5VHPRRAHEiC-_8_W-tkiWwJ-mb7eHOXXLJx6MqTAZjK6Q3m871PXJRfZuNyul9azsp-XjeluUX7jUJrw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+a+pharmacist-led+actionable+audit+and+feedback+intervention+for+improving+medication+safety+in+UK+primary+care%3A+An+interrupted+time+series+analysis&rft.jtitle=PLoS+medicine&rft.au=Peek%2C+Niels&rft.au=Gude%2C+Wouter&rft.au=Keers%2C+Richard&rft.au=Williams%2C+Richard&rft.date=2020-10-13&rft.pub=Public+Library+of+Science&rft.eissn=1549-1676&rft.volume=17&rft.issue=10&rft_id=info:doi/10.1371%2Fjournal.pmed.1003286&rft.externalDocID=2479468666 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |